Consilience Ventures

QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.

Jiva.ai is a pioneering no-code Agentic AI platform that empowers users across industries to create, evaluate, and deploy AI agents of any type, without requiring programming expertise. Jiva.ai's mission is to democratize AI technology, making it accessible to cross-sector businesses, and entrepreneurs. A key innovation of Jiva.ai is its focus on agentic AI, developing autonomous agents capable of proactively handling tasks such as supply chain monitoring, customer support, and financial portfolio management. This advancement positions Jiva.ai at the forefront of AI technology, addressing the growing demand for intelligent, self-directed systems. Jiva.ai supports multimodal AI, enabling the integration of many data types, including imaging, voice and text. This versatility has led to its adoption in diverse sectors, from healthcare and life sciences to marketing optimization and cybersecurity. We are able to merge AI models to make more accurate predictions in complex systems. Jiva.ai has garnered attention for its ability to rapidly prototype and deploy AI models, significantly reducing the time and expertise traditionally required for AI development. The platform's success in healthcare where, for example, it has been used to create high-fidelity diagnostics, showcases its potential to accelerate scientific discoveries and improve clinical outcomes. Jiva.ai is a multiple award-winning platform, most recently selected as one of the top 7 AI companies in Europe. It has partnered with organizations such as MongoDB and IBM HyperProtect as part of its ongoing growth strategy.

Cerebreon Technologies specializes in advanced data analytics, business management systems and process automation. Cerebreon Technologies Ltd. provides bespoke software solutions and expert consultancy services to enterprises with a mission to make high-end analytics accessible to all businesses, irrespective of their size or sector.